Strategic leadership Recent C-suite changes signal a refreshed leadership focus and potential openness to scalable partnerships. With Emily Schmitz appointed as CEO and a track record in managed care services, there’s an opportunity to align ActualMeds’ medication reconciliation capabilities with payer and hospital networks pursuing cost containment and improved outcomes.

Expansion potential Growth momentum evidenced by executive hires and ongoing technology partnerships suggests readiness to scale. Target health systems and hospital networks expanding care transitions programs, particularly where PODS or pharmacist-on-demand services can be integrated to reduce readmissions and optimize transitions of care.

Clinical validation Clinical trial inspiration and NIH-backed evidence underpin the value proposition. Position the BPMH solution as a proven risk-mitigation tool for hospitalizations, ER visits, and readmissions, with emphasis on integrating patient-reported data into EHR and HIE workflows for smoother care transitions.

Tech-enabled partnerships Active collaborations with Particle Health and a focus on AI-driven reconciliation highlight a modern tech stack and data interoperability. Approach health systems and clinical IT teams with integration-ready demonstrations showing streamlined data exchange, payer-provider alignment, and automated reconciliation at point of care.

Market positioning Revenue looks mid-market with a lean team, presenting a clear opportunity to upsell to mid-to-large hospitals and health networks seeking cost-of-care reductions. Leverage recent leadership changes and patient-centered outcomes focus to pitch scalable deployment, robust support, and measurable ROI.